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DOI 10.1016/j.ccr.2010.10.033SUMMARYMalignant astrocytic brain tumors are among themost lethal cancers. Quiescent and therapy-resistant neural
stem cell (NSC)-like cells in astrocytomas are likely to contribute to poor outcome.Malignant oligodendroglial
brain tumors, in contrast, are therapy sensitive. Usingmagnetic resonance imaging (MRI) and detailed devel-
opmental analyses, we demonstrated that murine oligodendroglioma cells show characteristics of oligoden-
drocyte progenitor cells (OPCs) and are therapy sensitive, and that OPC rather thanNSCmarkers enriched for
tumor formation. MRI of human oligodendroglioma also suggested a white matter (WM) origin, with markers
for OPCs rather than NSCs similarly enriching for tumor formation. Our results suggest that oligodendro-
glioma cells show hallmarks of OPCs, and that a progenitor rather than aNSCorigin underlies improved prog-
nosis in patients with this tumor.INTRODUCTION
Oligodendrogliomas comprise a glial fibrillary acidic protein
(GFAP) negative glioma, account for 5%–20% of gliomas, and
show morphology and markers associated with oligodendro-
cytes, myelin-forming cells in the brain. Postnatal oligodendro-
cytes arise from oligodendrocyte progenitor cells (OPCs), the
most abundant population of cycling cells in the adult brain (Daw-
son et al., 2003; Geha et al., 2010). OPCs are widely dispersed in
thesubventricular zone (SVZ), aneural stemcell (NSC)-rich region
lining the lateral ventricular walls, and as a resident populationSignificance
The relationship between oligodendroglioma cells and norma
structures arise from NSCs in the ventricular zone, an area tha
cyte progenitor cells (OPCs) located in WM constitute a seco
astrocytic tumors have been described to contain NSC-like tum
of tumor-initiating cells in oligodendroglioma remain poorly u
glioma cells share hallmarks of progenitors rather than NSCs.
glioma contributes to its responsiveness to therapy.
Canin white matter (WM) regions (Levison and Goldman, 1993;
Menn et al., 2006; Zhu et al., 2008). OPCs can be identified
through coexpression of platelet-derived growth factor receptor
a (PDGFRa), transcription factors Sox10 and Olig2, and the
neuroglial chondroitin sulfate proteoglycan 4 (NG2) (Chang et al.,
2000). Expression of NG2 is higher in oligodendrogliomas than in
the more frequently arising astrocytic tumors; however, lineage
relationships among oligodendrogliomas, NSCs, and OPCs
remain poorly understood (Shoshan et al., 1999). In this commu-
nication, we investigated and compared NSCs and OPCs as
potential cells of origin in murine and human oligodendroglioma.l stem and progenitor cells is uncertain. Most normal brain
t persists in adults and generates adult NSCs. Oligodendro-
nd postnatal reservoir for generation of glial cells. Whereas
or cells that are quiescent and therapy resistant; the features
nderstood. We show that mouse and human oligodendro-
Our results suggest that a progenitor origin for oligodendro-
cer Cell 18, 669–682, December 14, 2010 ª2010 Elsevier Inc. 669
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NG2+ Cells Propagate OligodendrogliomaRESULTS
Murine Oligodendrogliomas Develop in Association
with WM Tracts through Expansion of OPCs
To investigate oligodendroglioma development, we employed
a transgenic mouse glioma model driven by an activated allele
of EGFR, (v-erbB) under control of the human S100b promoter
(Weiss et al., 2003). Aberrant epidermal growth factor receptor
(EGFR) signaling in both NSCs and OPCs may contribute to oli-
godendrocytic tumors (Gonzalez-Perez et al., 2009; Ivkovic
et al., 2008). S100b is associated with mature astrocytes, epen-
dymal cells, select neuronal populations, and OPCs. In the adult
SVZ, S100b is expressed as GFAP+ cells lose NSC potential
(Hachem et al., 2005; Raponi et al., 2007). Mice expressing
v-erbB develop low-grade oligodendrogliomas, with expression
of v-erbB mRNA localized to the cerebellar granular cell layer,
subcortical WM, and SVZ (Weiss et al., 2003). Tumors arose
with increased grade and shortened latency (average 66 ±
5 days) in v-erbB-expressing mice deleted for p53 (E/p53/)
and were used in most experiments (see Figures S1A and S1B
available online).
To assess proliferation in SVZ prior to development of tumors,
we sacrificed mice at postnatal days 10 and 30 (P10 and P30).
BrdU labeling in SVZ at P10 and P30 was indistinguishable in
E/p53/ mice and p53/ littermates (Figures S1C–S1E). The
distribution of BrdU in GFAP+ proliferating NSCs, doublecortin+
neuroblasts, and Olig2+ glial progenitors was also comparable
in E/p53/ and p53/ mice (Figures S1F–S1H). These data
suggest that v-erbB affected neither proliferation nor differentia-
tion of SVZ NSCs, and are consistent with NSCs being S100b
(Raponi et al., 2007).
In contrast, tumor-bearing transgenic mice showed prolifera-
tion in stria terminalis, a WM structure adjacent to SVZ (Figures
1A and 1B, see inset). Also, irrespective of p53 status, symptom-
atic transgenic mice displayed massive proliferation in WM
regions such as the corpus callosum (CC), illustrated by Ki67
or BrdU labeling (Figure 1C). To further localize tumors, we
used MRI and postmortem histology in symptomatic transgenic
mice. T1-weighted imaging of a transgenic animal illustrates
a typical tumor within CC (Figure 1D). Tumor cells had character-
istic oligodendroglioma-like morphology (Figures 1E and 1F),
collectively suggesting that murine oligodendrogliomas arise in
WM regions.Murine Oligodendrogliomas Arise through Expansion
of OPCs
Glial progenitors, including NG2-expressing OPCs (Gonzalez-
Perez et al., 2009; Menn et al., 2006), express high levels of
Olig2, allowing us to distinguish these cells from NSCs and
prompting us to quantify the fraction of Olig2+ glial progenitor
cells that expressed NG2 in SVZ (Dawson et al., 2003). At P30,
E/p53/ mice showed a 3-fold increase in the fraction of
Olig2+ cells expressing NG2 in SVZ compared with controls
(Figures S1I–S1K). Further, all NG2+ cells coexpressed S100b
(inset in Figure S1J). These results suggest that OPCs expand
in the SVZ of E/p53/ mice. Although the SVZ is a region
enriched for NSCs, our data are consistent with expression of
v-erbB predominantly in OPCs rather than NSCs within the SVZ.670 Cancer Cell 18, 669–682, December 14, 2010 ª2010 Elsevier IncSince NG2+ OPCs are prominent in subcortical WM, we
analyzed Olig2+ cells expressing NG2 in CC at P30. Transgenic
mice (E/p53/) showed a 3-fold increase in the fraction of
Olig2+ cells expressing NG2 in CC compared with controls
(Figures 1G–1I). Tumor regions arising in WM tracts of
E/p53/ mice expressed NG2 (Figures 1J–1O). In cerebellum,
most tumor cells were found in the innermost WM (Figure 1O).
At P30, E/p53/ mice displayed high numbers of proliferative
cells in other WM tracts (Figures 2A–2D). These proliferative
lesions stained for oligodendroglial markers NG2 and Olig2,
and were negative for astrocytic marker GFAP (Figures 2E–2J).
WM tracts in mice are enriched for OPCs, prompting us to
investigate expression of additional OPC markers. NG2+ tumor
cells coexpressed S100b, the v-erbB transgene, and the
OPC markers PDGFRa, A2B5, Sox10, and Olig2 (Figure S2A).
This expression profile together with expression of the oligoden-
drocyte markers MBP and CNPase, and low levels of GFAP
are aligned with patterns in oligodendroglioma in humans.
Collectively, these data suggest that tumors in this model
arise from WM regions and express proteins normally found in
OPCs.
To determine whether altered gene expression in transgenic
OPCs contributed to tumors, we analyzed Sox10, a gene
required for terminal differentiation of OPCs, that also promotes
gliomagenesis (Johansson et al., 2004). We generated mice
doubly transgenic for S100b-v-erbB and NG2-DsRed (Zhu
et al., 2008), allowing us to identify and isolate DsRed+ NG2
cells. WM regions from E/p53/ mice (NG2-DsRed) were
pooled at P30, well before tumors arise. Tissues were microdis-
sected and analyzed by FACS, followed by RNA isolation and
real-time PCR (Figure S2B). Levels of Sox10 in NG2+ cells
were 5-fold higher in E/p53/ than in p53/ mice (p < 0.05),
suggesting that the S100b-v-erbB transgene regulates gene
expression in NG2+ cells, promoting tumorigenesis (Figure S2C).
These data demonstrate that expansion of OPCs in WM regions
precedes development of tumors, and suggest that oligodendro-
gliomas in these animals arise from NG2+ cells in WM regions.
Gene Expression in Murine Oligodendrogliomas
Demonstrate an OPC Rather Than a NSC Profile
It is important to clarify that tumor-initiating cells (TICs) define
a functional population of cells that are tumor propagating and
does not necessarily imply a relationship with a specific cell of
origin. TICs in human GBM typically constitute a minority popu-
lation and share features of NSCs including self-renewal, multi-
potency, and resistance to therapy (Bao et al., 2006; Bleau
et al., 2009; Singh et al., 2004; Stiles and Rowitch, 2008). To
study these properties, we isolated cells from SVZ, WM tracts,
and tumors of both E/p53/ mice and p53/ controls. Cells
in Neurobasal media (NB) supplemented with FGF-2 and EGF
were studied as acutely isolated, low-passage (less than five
passages), or high-passage (greater than five passages).
To delineate the relationship among v-erbB-expressing cells
isolated from SVZ and tumors (E/p53/), normal NSCs from
SVZ (p53/), and WM progenitors (p53/), we performed
real-time PCR for NSC and OPCs markers. Transgenic
(E/p53/) cells from SVZ and tumors expressed high levels of
OPC markers and low levels of NSC markers relative to normal
SVZ NSCs (Figure S2D). Interestingly, v-erbB-expressing.
Figure 1. NG2 Expression in WM Regions in Developing Oligodendrogliomas
Proliferating regions in transgenic mice (E/p53/) were identified by administering BrdU 2 hr before sacrifice.
(A and B) Identification of BrdU+ cells next to the SVZ in transgenic mice developing tumors. Higher magnification of BrdU labeling (arrows) in stria terminalis of
striatum, a WM region.
(C) Proliferation (Ki67+) in WM structures (arrows): cc, corpus callosum, ec, external capsule. To investigate if v-erbB expanded NSCs and their progeny at P30,
transgenic mice and nontransgenic mice were administered BrdU 2 hr before sacrifice (inset).
(D) T1-weighted MRI shows a supratentorial tumor (arrow) in a E/p53/ mouse.
(E) Pathology obtained after MRI shows tumor in WM (arrowheads).
(F) Tumor cells with round nuclei and perinuclear cytoplasmic retraction (arrows).
(G–I) NG2+/Olig2+ cells (*) in CC in control p53/mice (G) and in E/p53/mice (H), quantification of results are shown in (I). ***p < 0.001, Student’s t test. Values
are expressed as mean ± SEM.
(J–O) H&E staining of (J)–(L) and NG2 expression in (M)–(O) a transgenic mouse brain. Arrows indicate WM tracts, cb, cerebellum, ot, optic tract, sp, septum, ctx,
cortex, ob, olfactory bulb, hipp, hippocampus. (J and M) A parasagittal section shows multifocal tumors (*). (K and, N) Tumors along CC. Arrows in the inset (K)
indicate perinuclear halos. (L and O) Tumors arising in cerebellum. The innermost WM structure is indicated by arrow. Asterisk indicates molecular cell layers (*).
See also Figure S1.
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Figure 2. Expression of NG2 and GFAP in
Proliferative Regions in Premalignant Mice
(A) Illustration of coronal sections of a mouse
brain. Red dots represent brain regions that incor-
porated BrdU in P30 E/p53/mice at 2 hr. Lateral
ventricles (lv) are shown in blue. ec, external
capsule, cc, corpus callosum, ac, anterior commi-
sure, sp, septum pellucidum, st, stria terminalis,
ot, optic tract.
(B–D) Incorporation of BrdU (arrows).
(E–G) Expression of the early glial marker Olig2
and the astrocytic marker GFAP in BrdU+ cells.
(H–J) Coexpression of Olig2 and NG2 in BrdU+
cells.
See also Figure S2.
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NG2+ Cells Propagate Oligodendrogliomalow-passage cells isolated from SVZ, CC, and tumors showed
gene expression profiles similar to control cells isolated from
CC rather than SVZ (Figure S2E). In fact, levels of OPC markers
Sox10 and PDGFRa were elevated in acutely and low-passage
cells from E/p53/ mice compared with WM progenitors from
p53/ mice, suggesting that v-erbB was associated with
increased expression of these genes (Figures S2E and S2F).
In contrast to passaged SVZ cells from E/p53/ mice (Fig-
ure S2E), acutely isolated SVZ cells expressing v-erbB mRNA
showed no changes in Sox10 and Hes1 (NSCmarker) compared
with controls (Figure S2F). We confirmed for a subset of these
genes, differential protein expression in E/p53/ tumor cells
(10118T) compared with p53/ SVZ NSCs (Figure S2G). The
high expression levels of OPC rather than NSC markers in
v-erbB-expressing cells suggest that these cells are more
related to WM OPCs rather than SVZ NSCs.672 Cancer Cell 18, 669–682, December 14, 2010 ª2010 Elsevier Inc.V-erbB-Expressing Murine
Oligodendroglioma Cells
Differentiate intoOligodendrocytes
in Response to Inhibitors of MAPK
In contrast to SVZ NSCs, murine oligo-
dendroglioma cells showed efficient
proliferation independently of growth
factors (Figure 3A; Figures S3A and
S3B). Basal levels of pErk1/2 and pAkt
(in SVZ NSCs, grown in FGF-2 and EGF)
were reduced when compared with low-
passage E/p53/ cells (Figure 3B). We
next analyzed proliferation in NG2+
OPCs. Dividing BrdU+ low-passage cells
in SVZ NSC cultures from p53/ mice
were NG2-. In contrast proliferating
tumor cells were highly NG2+ (Figures
S3C and S3D). NG2+ cells from trans-
genic mice expressed both S100b and
v-erbB (Figures S3E–S3H). The fre-
quency of NG2+ cells in SVZ cultures
from E/p53/ mice was expanded in
and adjacent to SVZ, with unaltered
proliferation of SVZ NSCs (Figures S3I–
S3J). These results suggest that v-erbB
under control of the S100b promoter
promotes expansion of NG2+ OPCs.To modulate signaling pathways, we used MEK inhibitor
PD325901 (1 mM, PD) and PI3K/mTOR inhibitor LY294002
(10 mM, LY). Tumor cells from transgenic (E/p53/) mice were
incubated without EGF and FGF-2 for 24 hr. Inhibitors were
added (2 hr) followed by 100 ng/ml EGF (20 min) prior to lysis
(Figure S3K). To determine effects on low-passage v-erbB-
expressing murine oligodendroglioma (E/p53/), we incubated
cells for 7 days with PD (1 mM) and/or LY (10 mM). While PD was
more effective than LY in reducing proliferation of SVZ NSC
(p53/SVZ), both inhibitors were equally effective at reducing
proliferation of tumor cells (Figure S3L). Interestingly, inhibition
of MEK (but not PI3K/mTOR) induced oligodendrocyte-like
differentiation of the tumor cells (Figures S3M and S3N).
Incubation with PD differentiated acutely isolated murine
oligodendroglioma (31194T) cells into oligodendrocytes ex-
pressingO4, amarker of immature oligodendrocytes (Figure 3C).
Figure 3. Inhibition of MAPK Effects Differ-
entiation of Murine Oligodendroglioma
Cells
(A) Cells from three low-passage murine oligoden-
drogliomas or from p53/ SVZ were grown in the
absence (w/o GF) or presence of indicated growth
factors (7 days) on coated plates and quantified by
CyQuant proliferation assay.
(B) Immunoblot of pAkt and pErk1/2 in adherent
cells on coated plates from p53/ and E/p53/
mice. SVZ, subventricular zone, CC, corpus cal-
losum, T, tumor.
(C and D) Immunofluorescent analyses of NG2+
and O4+ cells from a representative murine oligo-
dendroglioma without or with treatment with 1 mM
PD for 7 days (C), quantification data shown in (D).
Scale bar: 40 mm.
(E and F) Immunofluorescent analyses for the
neuronal marker Map2ab+ and the glial marker
GFAP of SVZ NSCs without or with treatment
with 1 mM PD for 7 days.
Values are expressed as mean ± SEM. See also
Figure S3.
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NG2+ Cells Propagate OligodendrogliomaPD reduced the percentage of NG2+ tumor cells (67% ± 4%
versus 21% ± 5%, p < 0.001) and increased the percentage of
O4+ cells (11% ± 3% versus 51% ± 3%, p < 0.01) (Figure 3D),
specifically inducing oligodendroglial, but not neuronal or astro-
glial, differentiation. Incubation of SVZ NSCs with PD induced
neuronal (Map2ab: 32% ± 4% versus 3% ± 2%, p < 0.001)
and astroglial (GFAP: 29% ± 2% versus 5% ± 1%, p < 0.001),
but not oligodendroglial differentiation (Figures 3E and 3F).
These results suggest that the S100b promoter drives expres-
sion of v-erbB in WM OPCs, resulting in increased pErk1/2,
increased proliferation, and formation of oligodendroglioma in
transgenic mice.
Oligodendroglioma Cells Show Restricted
Differentiation and Sphere Formation
Wenext investigated E/p53/ oligodendroglioma cells formulti-
potency and sphere formation. Both ciliary neurotrophic factor
(CNTF) and bone-morphogenic protein 4 (BMP4) induce robust
astroglial differentiation in low-passage NSC cultures. Incuba-
tion with these factors for 7 days reduced the expansion of
low-passage SVZ NSCs and astrocytoma (GFAP-Ras) cells
(Ding et al., 2001), with more modest effects on low-passage oli-
godendroglioma cells (Figures 4A–4C), suggesting that oligo-Cancer Cell 18, 669–682, Ddendroglioma cells fail to respond to
morphogens that block proliferation in
both NSCs and astrocytoma cells.
To further assess themultilineage com-
petence of oligodendroglioma-derived
cells, we treated cells with morphogens
known to differentiate NSCs into neurons
(forskolin), astrocytes (CNTF or BMP4),
and oligodendrocytes (combination of
T3 and IGF-1), analyzing both acutely iso-
lated SVZ NSCs (p53/) and tumor cells
(31194T). Consistent with a limited differ-
entiation potential of OPCs, NG2-ex-pressing tumor cells responded to forskolin by differentiating
into O4+ oligodendrocytes rather than neurons or astrocytes
(Figures 4D and 4E). While BMP4 showed an inhibitory effect
on oligodendrocyte differentiation, neither CNTF nor T3/IGF1
significantly affected differentiation in oligodendroglioma cells
(Figures 4D and 4E).
In contrast to the limited differentiation potential of E/p53/
oligodendroglioma cells, p53/ SVZ NSCs were multipotent
and showed robust differentiation into neurons (forskolin), astro-
cytes (CNTF or BMP4), and oligodendrocytes (T3/IGF-1) (Figures
4D and 4F). In tumors from a murine astrocytoma model (GFAP-
Ras), acutely isolated tumor cells expressed CD15 and readily
differentiated into astrocytes in response to forskolin, CNTF, or
BMP4 (Figure S4A). Furthermore, continued passage of these
astrocytoma cells enriched for the NSC marker CD15 and not
the OPCmarker NG2 (not shown). Thus, NSCs andmurine astro-
cytoma cells both show multipotent differentiation potential,
while differentiation potential in murine oligodendroglioma cells
is more restricted.
To determine if the restricted differentiation of murine oligo-
dendroglioma cells was differentially associated with either
NG2+ or NG2 subpopulations, we acutely isolated tumor cells,
and separated NG2+ and NG2 populations using FACS. Oneecember 14, 2010 ª2010 Elsevier Inc. 673
Figure 4. Expression of OPC and NSC Markers in NG2+ Oligodendroglioma Cells
(A–C) Low-passage SVZNSCs, GFAP-Rasmurine astrocytoma cells, andmurine oligodendroglioma cells were incubatedwith CNTF or BMP4 for 7 days and their
proliferation was measured using CyQuant proliferation assay.
(D–F) Potential of acutely isolated SVZ NSCs and murine oligodendroglioma cells to differentiate into three neural cell lineages.
(D) Murine oligodendroglioma cells or p53/ spheres from SVZ were stained for NG2, O4, Map2ab, and GFAP under differentiating conditions for 7 days in
response to forskolin, CNTF, and T3/IGF1. Scale bars, 40 mm.
(E and F) Quantification of response for acutely isolated murine oligodendroglioma cells and SVZ NSC cultures, to agents shown in (D), and to BMP4.
Values are expressed as mean ± SEM. See also Figure S4.
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NG2+ Cells Propagate Oligodendrogliomaday after isolation many NG2 cells displayed an oligodendro-
cyte phenotype, whereas NG2+ cells remained undifferentiated
morphologically, continuing to divide (Figure S4B). Enzymatic
dissociation of murine oligodendroglioma cells cleaved the
NG2 epitope, less with accutase than with trypsin (Figure S4C
and not shown). Immediately after accutase dissociation, cells
analyzed by FACS showed a pure NG2 cell fraction (Fig-
ure S4C). Incubation of NG2 and NG2+ oligodendroglioma
cells for 7 days with forskolin revealed that NG2+, but not
NG2 cells, could differentiate into O4+ oligodendrocytes
(Figures S4D and S4E). Few tumor cells (9% ± 4%) in NG2
sorted cultures expressed neuronal marker Map2ab. In contrast
to NSC cultures (p53/SVZ), this number was unchanged in
response to forskolin. These results suggest that NG2+ cells
can be differentiated along the oligodendrocytic lineage. We
found that NG2+ oligodendroglioma cells in this mouse model
show poor sphere-formation capacity, and that CD15 labels
a population of sphere-forming cells in both tumors and the non-674 Cancer Cell 18, 669–682, December 14, 2010 ª2010 Elsevier Inctransformed brain (Figures S4F and S4G). To study how passage
affected the fraction of cells expressing NG2 or the NSC marker
CD15, we cultured tumors from transgenic mice and performed
FACS at different passages. Continued passage enriched for
NG2+ cells due to death of nontumor cells and fast proliferation
of NG2+ tumor cells (Figure S4H). Expression of CD15 did not
change (Figure S4I).
Progenitor Rather Than NSC-Like Murine
Oligodendroglioma Cells Drive Tumor Formation inMice
In murine astrocytoma models, sphere-forming tumor cells
effectively establish tumors in vivo (Alcantara Llaguno et al.,
2009; Marumoto et al., 2009), with the NSCmarker CD15 enrich-
ing for sphere-forming TICs in human GBM (Son et al., 2009).
Consistent with a progenitor rather than an NSC origin in murine
oligodendrolioma, cells isolated from tumors of E/p53/ mice
displayed amajor population of NG2+ cells that was nonoverlap-
ping with a minor CD15+ population (Figure 5A). To investigate.
Figure 5. Assaying Tumorigenicity in Response to Enrichment for the OPC Marker NG2 or the NSC Marker CD15
(A) Expression of the NSC marker CD15 (arrows) and the progenitor marker NG2, in FACS-sorted murine oligodendroglioma cells.
(B) Allografting of 1000 low-passage tumor cells (10118T) analyzing tumor-forming ability of CD15- and CD15+ NSC -like cells (n = 5 per group) and survival of
mice.
(C) Animal survival following injection of 50 cells acutely isolated from tumor 30698, comparing NG2+, NG2CD15, and NG2CD15+ cells.
(D) Fraction of NG2+ cells shown as a function of passage (green, acutely isolated tumor cells, blue, low passage; red, high passage).
(E and F) Tumorigencity of NG2+ cells and survival of graftedmice. Tumors isolated from E/p53/mice were FACS-sorted cells based on expression of NG2. (E)
Tumor formation in mice orthotopically grafted with 1000 cells (n = 5 mice per group) showing high expression of NG2 (NG2 high), low expression of NG2 (NG2
low), and NG2 cells (NG2 neg). (F) In a separate experiment, 50 acutely isolated (31193T), low-passage (10118T), or high-passage (24314T) NG2+ or NG2
tumor cells were grafted orthotopically. Tumor burden is indicated by surviving fraction.
See also Figure S5.
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NG2+ Cells Propagate Oligodendrogliomawhether CD15+ cells could initiate oligodendroglioma, we
grafted 1000 low-passage CD15 (CD15 neg) or CD15+ (CD15
high) tumor cells into recipient mice. CD15+ NSC like cells iso-
lated from tumors of E/p53/ mice were nontumorigenic (Fig-
ure 5B). In contrast, grafting of 50 acutely isolated NG2+CD15-
tumor cells resulted in tumors in three of four mice (Figure 5C).
Control mice injected with NG2CD15 or NG2CD15+ cells
showed no tumors over 60 days.
Since continued passage of tissues from E/p53/ mice en-
riched for NG2 expression (Figure 5D), we used low-passage
cells, sorted these into NG2 low, intermediate, or high groups
and grafted 1000 tumor cells into recipient mice. Expression of
NG2 correlated with tumorigenicity (Figure 5E). To further define
the efficiency by which NG2-directed FACS enriched for TICs,
we grafted 50 NG2+ or NG2- tumor cells from acutely, low-,
and high-passaged tumors into recipient mice. Independently
of passage, NG2+ cells were more tumorigenic than NG2 cells
(Figure 5F). All tumors showed oligodendroglioma-like mor-
phology, with transplanted and primary tumors showing the
same OPC markers (data not shown).
A dye-excluding minority side-population (SP) of tumor cells
also shows properties of NSCs (Murayama et al., 2002). To
investigate the SP inmurine oligodendroglioma, we FACS sorted
tumor cells from E/p53/mice and compared tumorigenicity in
SP and non-SP (NSP) tumor cells injected into recipient mice.
The SP (0.9% ± 0.7% of all tumor cells) was abolished by incu-
bation with 20 mM verapamil, known to block SP-enriched multi-
drug transporters (Figure S5A). No significant difference in
tumorigenicity was observed between SP and NSP cells (Fig-
ure S5B). Both the SP and S100A6 have been suggested toCanmark rare NSC-like tumor cells in this model (Harris et al.,
2008). We observed broad expression of S100A6 in all tumors
(Figure S5C). Our results suggest that neither the SP nor
S100A6 enrich for TICs in this model.
The cell-surface marker CD133 also enriches for TICs in
human glioma (Singh et al., 2004). The corresponding murine
protein prominin, was expressed at low levels in v-erbB+ tumors
(five of six tumors showed <1%prominin+ cells), and overlapped
with both the NG2- and NG2+ populations (Figures S5D and
S5E). The latency of tumor formation in recipient mice and ability
to form tumor spheres in vitro reflected the fraction of NG2+ cells
in both prominin and prominin+ fractions (Figures S5F–S5H). In
a separate experiment, few CD15+ NSCs (p53/SVZ) incorpo-
rated BrdU after a 24 hr pulse whereas the majority of NG2+ oli-
godendroglioma cells (E/p53/) were labeled (Figures S5I–S5L).
Collectively, these results demonstrate that NG2 labels a major
population of fast-dividing tumor cells displaying higher tumori-
genicity than NG2- cells in murine oligodendroglioma.
NG2+ and NG2- Oligodendroglioma Cells Are Sensitive
to Temozolomide
To correlate the OPC origin with response to alkylator therapy
in oligodendroglioma, we incubated SVZ NSCs, murine oligo-
dendroglioma cells, and murine astrocytoma (GFAP-Ras)
cells with temozolomide (TMZ, 10–100 mM). In contrast to SVZ
NSC and murine astrocytomas (Figures S6A and S6B), murine
oligodendrogliomas and OPCs (p53/CC) were highly TMZ-
sensitive (Figures 6A–6E; Figure S6C). Treatment of NG2 and
NG2+ fractions showed both populations to have equivalent
sensitivity to TMZ (Figure 6F). These data suggest further thatcer Cell 18, 669–682, December 14, 2010 ª2010 Elsevier Inc. 675
Figure 6. Tumorigenicity and Response of NG2+ Oligodendroglioma Cells to Temozolomide
Human oligodendrogliomas differ from astrocytomas in their increased sensitivity to alkylating agents.
(A and B) Adherent low-passage murine oligodendroglioma cells (10118T) were treated with 100 mM TMZ for 7 days (TMZ100).
(C and D) Immunofluorescence staining of representative tumor cells demonstrating expression of NG2 before and after incubation with TMZ.
(E and F) Proliferation assay demonstrating response of acutely isolated murine oligodendroglioma cells (30698T) to increasing concentrations of TMZ
(0–100 mM), as a function of NG2 status.
(G and H) Response of low-passage human oligodendroglioma cells (SF8245) to TMZ, as a function of NG2 status.
(I) Flow cytometry of SF7987 demonstrating the fraction of NG2+ cells in an acutely isolated 1p/19q deleted grade II oligodendroglioma.
(J) FACS analyses: expression of NG2 in high-passage (red) GBMs, acutely dissociated oligodendrogliomas (green), and a low-passage oligodendroglioma
(blue).
(K and L) Surviving fraction of mice grafted orthotopically with 1000 NG2+ or NG2 cells per mouse from acutely isolated oligodendroglioma SF7987 and from an
acutely isolated grade II oligodendroglioma SF7891 (showing EGFR expression and p53 mutation).
Values are expressed as mean ± SEM. See also Figure S6.
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with improved response to alkylating agents.
To determine relevance, we isolated human oligodendro-
glioma cells from a patient with a grade II oligodendroglioma
(SF8245). As a comparison, we also isolated tumor cells from
a patient diagnosed with a grade II astrocytoma associated
with the lateral ventricles (SF8138), and studied low-passage
primary human GBM cells (SF6969). When low-passage human
tumor cells were cultured in neurobasal media (NBE, see Supple-
mental Experimental Procedures) on coated plates and incu-
bated for 7 days with 10–100 mM TMZ, oligodendroglioma cells
proved more sensitive than either astrocytoma or primary GBM
cells (Figure 6G; Figures S6DandS6E). Interestingly, both human
GBM and astrocytoma cultures showed enrichment of CD15+
cells after treatment with TMZ, with the GBM also demonstrating
higher levels of CD133 and podoplanin (not shown). Like murine
oligodendroglioma cells, human oligodendroglioma cells, irre-
spective of NG2 status, were similarly sensitive to TMZ (Fig-
ure 6H). These human and murine data collectively suggest that
a progenitor-like phenotype may underlie sensitivity of oligoden-676 Cancer Cell 18, 669–682, December 14, 2010 ª2010 Elsevier Incdroglioma cells to TMZ, and that NSC-like properties reciprocally
underlie relative resistance to TMZ in astrocytic tumors.
NG2+ Cells in Human Oligodendrogliomas
Are Highly Tumorigenic
To study tumorigenicity of NG2+ cells in human glioma, we
dissociated tumor cells, grown in NBE supplemented with
FGF-2 and EGF, from two patients diagnosedwith primary grade
II oligodendroglioma (SF7987 and SF7891). Flow cytometry veri-
fied expression of NG2 in a significant fraction of all samples
(Figures 6I–6J). Interestingly, continued passage in vitro of
human oligodendroglioma cells (SF8245) cultured in NBE sup-
plemented with FGF-2 and EGF, led to further enrichment for
NG2, while similar propagation of primary human GBM enriched
for CD15 (data not shown).
To study tumorigenicity, we fractionated acutely isolated
SF7987 oligodendroglioma cells followed by orthotopic grafting
of 1000 NG2+ or NG2 cells. Three of four mice injected
with NG2+ oligodendroglioma cells developed tumors after
5–8 months. No tumors (zero of four) established from.
Figure 7. Association with WM and OPC
Expression Profile in Human Oligodendro-
gliomas
(A) Grade II–III gliomas lacking frank contrast-
enhancement on T1-weighted MRI were subclas-
sified based on association with the lateral
ventricles and measurement of the apparent diffu-
sion coefficient (ADC) according to the flow chart.
(B) Example illustrating distance between edge of
tumor and lateral ventricle for astrocytoma grade
III (A–III), and 1p/19q codeleted oligodendro-
glioma (O–II).
(C) T1-weighted spoiled gradient echo and T2-
weighted fast low angle inversion recovery (FLAIR)
images were used to localize the tumor within the
brain parenchyma. The next two images were
acquired with a diffusion-weighted imaging tech-
nique that is sensitive to fluid mobility within the
tumor. Image maps of the ADC and the fractional
anisotropy (FA) highlight regions of isotropic and
directional fluid movement, respectively. Repre-
sentative images of tumors located within the
white matter: one subset typically exhibited well-
circumscribed borders (A–II) on the FAmaps while
a second subset typically showed diffuse borders
(O–II) (cf. magnifications in C).
(D) The majority of grade II–III astrocytomas were
touching the lateral ventricles (Type 1) and had
a well-circumscribed border on both the anatomic
MRI (T2-weighted and FLAIR) as well as on the
diffusion-weighted FA map of directional water
mobility along WM structures. A second group of
astrocytomas (Type 2) were not touching the
lateral ventricles but showed a pattern on FA
maps with well-circumscribed borders similar to
Type 1 astrocytomas. A third group of astrocy-
tomas (Type 3) were away from the ventricles
and showed diffuse borders on FA maps similar
to (E) 1p/19q oligodendrogliomas.
(F) Gene expression patterns in human oligoden-
droglioma cells and WM glial progenitors (OPCs).
Quantitative real-time PCR identified relative
abundance of transcripts in A2B5+ human oligo-
dendroglioma cells (n = 3) and human astrocy-
tomas (n = 4) relative OPCs (n = 3) normalized to
their A2B5- remainders. Scale bars, 2 cm.
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acutely isolated NG2+ low grade oligodendroglioma cells
SF7891 (two of four), died after almost 1 year, whereas all mice
injected with NG2 cells survived (Figure 6L). These results
suggest that NG2+ cells from human oligodendrogliomas prolif-
erate and are highly tumorigenic.
HumanOligodendrogliomas Localize toWMandExpress
OPC Markers
If oligodendrogliomas arise from OPCs rather than NSC-like
cells, then do these tumors associate with white matter regionsCancer Cell 18, 669–682, Dwhere NG2+ OPCs normally reside? To
address this question, we studied 47
grade II and III nonenhancing oligoden-
drogliomas and astrocytomas. Use of
small lower grade tumors simplified local-ization to WM or ventricular regions. Further, the fact that tumors
did not exhibit contrast-enhancement reduced the chances of
erroneously identifying the boundaries of leaky vasculature as
the boundaries of tumor infiltration.
Using T1-weighted spoiled gradient echo (SPGR) and T2-
weighted fast low angle inversion recovery (FLAIR) MRI images,
we determined whether 47 grade II–III gliomas were touching the
lateral ventricles (Figure 7A). We hypothesized that gliomas
touching the lateral ventricles were astrocytomas (Figure 7B).
For the remaining gliomas, the diagnosis was predicted using
FA and apparent diffusion coefficient (ADC) maps, highlightingecember 14, 2010 ª2010 Elsevier Inc. 677
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formed a qualitative assessment of the FA map to classify as oli-
godendroglioma (diffuse edges) or astrocytoma (well-circum-
scribed borders) and then confirmed the classification by
calculating the median normalized ADC value (Figure 7C). The
qualitative and quantitative assessments matched in 18 of 20
cases that did not touch the ventricles. When they did not match,
the ADC value was used because of the previously reported
predictive value (Khayal et al., 2009). The majority of astrocy-
tomas (Type 1: 21/34) were touching the lateral ventricles (Fig-
ure 7D). Based on ADC values, we were able to distinguish
between five astrocytomas (Type 2, ADC: 2.1 ± 0.1) and oligo-
dendrogliomas (ADC: 1.5 ± 0.02 located), not touching the
ventricles. A diagnosis for a third group of eight astrocytomas
(Type 3) could not be predicted based on location or ADC values.
All human oligodendrogliomas showing loss of chromosomes 1p
and 19q (11/11) were associated with WM tracts rather than
lateral ventricles (Figure 7E), consistent with an origin from WM
progenitor cells. These results suggest that localization of
gliomas and diffusion pattern on MRI may be useful future tools
to subclassify oligodendrogliomas and astrocytomas with an
OPC or NSC signature.
Based on these data, we predicted that progenitor cells within
human oligodendroglioma would express transcripts consistent
with human WM glial progenitors (here denoted OPCs), rather
than with that of ventricular zone NSCs. To test this, we used
magnetic cell immunosorting using an antibody against A2B5,
which recognizes glial progenitor cells. A2B5 is expressed
in the majority of tumor cells in oligodendroglioma (Ogden
et al., 2008), and is typically coexpressed with NG2 (Sim et al.,
2006). The relative abundance of a set of NSC- and OPC-related
genes was compared in A2B5+ cells isolated from grade II
human oligodendrogliomas (n = 3), astrocytomas (n = 4), and
human OPCs and normalized to their depleted (A2B5)
remainder. In a set of 91 cell-type and pathway-specific genes,
15% and 34% of the studied genes in oligodendroglioma
and astrocytoma, respectively, showed significantly (p < 0.05)
different mRNA expression levels compared with human OPCs
(Figure 7F). Astrocytomas expressed lower levels of the OPC-
related genes CSPG4 (NG2), Nkx2.2, and PDGFRa, compared
with OPCs. Similar levels of the OPC-related genes (NG2,
Olig2, Nkx2.2, PDGFRa, and Sox11) and NSC-related genes
(Nestin, Sox2, Sox9, Musashi1/2) in human oligodendroglioma
cells and OPCs suggest a progenitor rather than a stem-cell
origin.
Human Oligodendroglioma Cells Show Limited Sphere
Formation and Differentiation Potential
We next investigated sphere formation and multipotency in
human oligodendroglioma. Human tumors were acutely isolated
and cultured in N5media, NBEmedia, orM41media supplement
with N1 and FGF2 (see Supplemental Experimental Procedures).
An oligodendroglioma isolated from frontal cortex grew as
elongated cells on coated plates in NBE (SF8245) (Figures 8A
and 8B). Incubation in M41 media resulted in slower growth
along with differentiation into cells showing oligodendroglial
morphology (inset in Figure 8B). Some oligodendrogliomas
expanded in NBE grew as clusters rather than uniform spheres
on ultralow adherent plates (Figure 8C).678 Cancer Cell 18, 669–682, December 14, 2010 ª2010 Elsevier IncTo evaluate the ability to form spheres, we plated cells from
three low-passage grade IV astrocytomas (primary GBMs), an
acutely isolated grade II astrocytoma (SF8138), and two acutely
isolated grade II oligodendrogliomas in NBE (Figure 8D). In
contrast to unsorted, NG2+, and NG2 oligodendroglioma cells,
four astrocytic tumors efficiently formed spheres. These results
suggest that human oligodendrogliomas are deficient at clono-
genic expansion, unlike either primary NSCs or cells derived
from astrocytomas or GBMs.
We assayed proliferation and differentiation potential by incu-
bating human oligodendroglioma culture SF8245 for 2 hr with
BrdU. Approximately 10% of NG2+ cells incorporated BrdU
and expressed the glial progenitor marker Nkx2.2 (Figure 8E).
The NG2+ cells expressed nestin (Figure 8F) but at lower levels
than GBM cells (Figures S7A–S7C). We next incubated human
oligodendroglioma cells (passaged once) with forskolin, BMP4,
and T3/IGF to induce differentiation along the three neural cell
lineages. Similar to murine oligodendrogliomas, neither BMP4
nor a combination of T3 and IGF1 induced differentiation in this
human oligodendroglioma (Figure 8G). Also similar to the trans-
genic mouse model, incubation with forskolin reduced the levels
of NG2+ oligodendroglioma cells (79% ± 6% versus 33% ± 6%,
p < 0.01) and increased the levels of O4+ oligodendrocyte-like
cells (0% ± 0% versus 7% ± 0.6%, p < 0.001) (Figures 8G–8I).
A significant fraction (13% ± 1%) of the tumor cells expressed
the immature neuronal marker TujI, suggesting ability to differen-
tiate into neurons. However, forskolin did not increase neuronal
differentiation of human oligodendroglioma cells. Incubation of
grade II human oligodendroglioma cells (SF8245) with the MEK
inhibitor PD325901 (1 mM) similarly reduced the fraction of
NG2+ cells (79% ± 6% versus 32% ± 4%, p < 0.01) and induced
expression of O4+ oligodendrocyte-like cells (0% ± 0% versus
8% ± 2%, p < 0.01) (Figures S7D and S7E). These results are
aligned with those obtained using murine v-erbB-expressing oli-
godendrogliomas, and suggest that human oligodendroglioma
cells are not tripotent, mainly differentiating into oligodendro-
cyte-like cells.
DISCUSSION
Oligodendrogliomas Show Hallmarks of OPC Rather
than NSC
Recent studies suggest a relationship between NSCs and their
malignant counterparts. However it is equally tenable that in
the course of malignant progression, restricted progenitors or
even differentiated cells may acquire properties associated
with TICs: self-renewal, multipotent differentiation, and asym-
metric division. It is entirely possible that tumor cells with
a progenitor-like phenotype could arise from stem cells that
subsequently commit to a progenitor lineage (e.g., BCR-Abl
mutations in stem cells giving rise to myeloid leukemia [Castor
et al., 2005]), or from a progenitor that subsequently dedifferen-
tiates into a more stem-like cell (Akala et al., 2008). Given these
caveats, it is important to distinguish between the normal cells
from which the tumor arises, and the cells that are capable of
propagating tumors following transplantation.
Unlike NSCs, OPCs undergo a restricted number of cell divi-
sions before they differentiate, a timing mechanism partly
controlled by p27Kip1 (Durand et al., 1997). Since expression.
Figure 8. Sphere Formation and Differentiation Potential of Human Oligodendroglioma Cells
(A–C) Cells were isolated from a human 1p/19q deleted oligodendroglioma (T2-weighted FLAIR image in A, SF#8245) and cultured as adherent (M41 media in
inset, B) or clusters (C).
(D) Sphere formation potential in NG2+ and NG2- cells from two acutely isolated 1p/19q deleted oligodendrogliomas.
(E and F) Incubation of cells from (A) with BrdU 2 hr before fixation, followed by staining for OPC-related genes NG2 and Nkx2.2, and stem cell marker Nestin.
(G–I) To investigate differentiation, we incubated tumor cells that had been passaged once, with forskolin, BMP4, or T3/IGF1 (7 days). Quantification (G) with
representative images (H and I) demonstrating staining with NG2 and O4 in response to forskolin. Values are expressed as mean ± SEM.
See also Figure S7.
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drogliomas is inversely correlated with p27Kip1 levels (Fan et al.,
2003; Fiano et al., 2003), this timing mechanism might be dysre-
gulated in both murine and human oligodendroglioma cells,
such that tumor cells continuously self-renew and are unable
to differentiate.
OPCs immortalized with an activated, point-mutated erbB2
oncogene differentiate into immature and mature oligodendro-
cytes in response to forskolin or erbB2 inhibition (Gobert et al.,
2009). Similar to these OPCs, NG2-expressing oligodendro-
glioma cells in our studies responded to forskolin or a MEK
inhibitor by differentiating into O4+ oligodendrocytes (and not
into astroglia or neurons), whereas BMP4 treatment inhibited
oligodendroglial differentiation.
Nuclear export of Olig2 is essential for complex formation
between STAT3 and the transcription activator p300, allowing
CNTF-induced differentiation in NSCs and OPCs (Setoguchi
and Kondo, 2004). High nuclear expression of Olig2 in NG2+ oli-
godendroglioma cells might therefore explain why these cells
failed to differentiate in response to CNTF. Interestingly, some
NG2-sorted tumor cells expressed the neuronal markerMap2ab,
suggesting that these cells did differentiate into neurons. SimilarCanto the v-erbB-driven murine oligodendrogliomas, cultures of a
1p/19q deleted grade II oligodendroglioma (SF8245) contained
a subpopulation of cells expressing the neuronal marker TujI,
and displayed oligodendroglial differentiation in response to
forskolin, T3/IGF1, or a MEK inhibitor. Collectively, these data
suggest that murine oligodendroglioma cells show a gene
expression profile consistent with OPCs, and are bipotent rather
than multipotent, differentiating mainly into oligodendrocytes.
Our previous study in mice transgenic for S100b-v-erbB
showed tumors to arise in supratentorial and hindbrain locations
(Weiss et al., 2003). Mutation at p53 led to increased grade and
penetrance, while also promoting a more supratentorial localiza-
tion. Perhaps relevant to these data, 13% of oligodendrogliomas
and 25% of high-grade gliomas show p53 mutations, whereas
mutations in p53 are rare in medulloblastoma, a tumor of the
posterior fossa (Adesina et al., 1994). This caudal-rostral shift
of tumors suggests that p53 plays region-specific roles in regu-
lating proliferation, differentiation, and senescence in NSCs and
progenitors during brain development, which influences localiza-
tion of tumors (Marumoto et al., 2009). We cannot exclude an
NSC or radial glial origin for tumors arising in the posterior fossa
region. However, S100b is expressed in embryonic radial gliacer Cell 18, 669–682, December 14, 2010 ª2010 Elsevier Inc. 679
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mainly localized to glia in the cerebellar WM (Vives et al., 2003),
the region where we observed most NG2+ oligodendroglioma
cells.
Loss of chromosomes 1p and 19q occurs commonly in human
oligodendroglioma, especially in proneural tumors, while over-
expression of EGFR and loss of p53mark only a subset of tumors
(Ducray et al., 2008). Interestingly, a minority of tumors in the
v-erbB model shows loss of the distal part of chromosome 4
that corresponds to human 1p (Weiss et al., 2003). We demon-
strate that OPC-like human oligodendroglioma cells from both
1p/19q and EGFR-driven tumors were highly tumorigenic. MRI
analyses from patients with grade II–III gliomas demonstrated
that oligodendrogliomas and astrocytomas could be subclassi-
fied based on MRI diffusion patterns (Khayal et al., 2009) and
association with the lateral ventricles, a NSC-rich region. Inter-
estingly, all 1p/19q deleted tumors arose in WM regions, while
two EGFR-driven p53 mutant human tumors were associated
with the lateral ventricles.
Despite the association of different tumors with specific brain
regions, the cell of origin in human glioma remains uncertain.
Recent subclassifications have demonstrated a classical group
of primary GBMs with high levels of the NSC marker nestin
and EGFR (Verhaak et al., 2010), and a mesenchymal group
controlled by a transcriptional network that transforms NSCs
(Carro et al., 2010). These two subclasses of primary GBMs
may thus arise from transformation of NSCs. A proneural group
of GBMs displays mutation of IDH1 and shows high levels of the
OPC-related genes Nkx2.2, Olig2, and PDGFRa (Brennan et al.,
2009; Verhaak et al., 2010). In contrast to other groups of GBMs,
the gene expression profile of proneural GBMs was aligned with
cultured oligodendrocytes (Verhaak et al., 2010), suggesting that
IDH1 mutant gliomas may arise from OPCs rather than dediffer-
entiated astrocytes or NSCs. Proneural oligodendrogliomas also
show 1p/19q loss, and express neuronal markers consistent
with origin from a bi-potential progenitor capable of generating
both oligodendrocytes and neurons (Ducray et al., 2008).
NG2, but Not NSC Markers, Selects for High
Tumorigenicity in Oligodendroglioma
The NSC markers CD133 (prominin), CD15, and the dye-
excluding SP enrich for highly tumorigenic cells in the brain
tumors medulloblastoma and astrocytomas, in both mice and
humans (Bleau et al., 2009; Marumoto et al., 2009; Read et al.,
2009; Singh et al., 2004; Son et al., 2009). In our studies, isolated
CD15+ cells from murine oligodendroglioma, were unable to
form tumors, whereas tumorigenicity of rare CD133+ tumor
cells could be explained by partial overlap with the OPC marker
NG2. The discrepancy in tumorigenicity between SP and NSP
cells between our study and a previous report could reflect
NG2+ cells in the NSP (Harris et al., 2008). Higher levels of
NG2, PDGFRa, Nkx2.2, Sox2, and S100b were reported in the
SP compared with the NSP, suggesting that the NSP contained
fewer NG2+ tumor cells (Harris et al., 2008). We observed NG2+
cells in both SP and NSP, perhaps explaining the similar latency
between these groups in our experiments.
In contrast to results using NSC-basedmarkers, we found that
NG2 enriched for tumor formation in vivo, in both murine and
human oligodendroglioma. Our data suggest that under these680 Cancer Cell 18, 669–682, December 14, 2010 ª2010 Elsevier Incconditions, NG2+ cells showed significantly higher (but not
exclusive) tumorigenicity compared with NG2 oligodendro-
glioma cells. Enzymatic treatment with accutase and/or differen-
tiation of NG2CD15+ cells into NG2+ cells could contribute to
the abundance of NG2+ cells that accumulated over time in
cultured NG2 fractions and might explain why grafting large
numbers of NG2 cells led to tumors in recipient mice.
Progenitor Features Contribute to Improved Outcome
in Oligodendroglioma
A transcriptional network in gliomas similar to either NSCs or
OPCs, along with distinct chromosomal changes, may underlie
differential response to alkylating agents and other therapies.
We observed that murine SVZ NSC and human astrocytoma
cultures were relatively resistant to treatment with TMZ. In
contrast, murine OPCs andOPC-like tumor cells from transgenic
mice and human oligodendrogliomas were highly sensitive.
These results suggest that a progenitor origin contributes to
the relative therapy-sensitive nature of oligodendroglioma.
Parenchymal localization, MRI data, and immunohistochemical
markers may help to select the appropriate glioma-selective
therapy, in conjunction with an OPC or NSC signature related
to specific chromosomal aberrations.
Collectively, our data suggest that murine oligodendroglioma
arise from NG2-expressing WM OPCs rather than NSCs. We
demonstrate that NG2+ oligodendroglioma cells express genes
and proteins associated with OPCs rather than NSCs, that NG2+
oligodendroglioma cells show limited sphere formation, consis-
tent with a progenitor population, and that NG2+ oligodendro-
glioma cells are lineage restricted. NG2-expressing cells from
both mouse and human oligodendroglioma displayed high
tumorigenicity and respond to both alkylating and differentiating
agents. We show that these oligodendroglioma cells are neither
chemo-resistant nor quiescent and suggest that a progenitor
origin for these cells underlies their chemosensitivity. Our results
suggest that oligodendroglioma arises from NG2-expressing
cells in WM regions, and links the therapy-responsive nature of
this tumor to a progenitor origin.
EXPERIMENTAL PROCEDURES
Mice
Mice transgenic for S100b-verbB (Weiss et al., 2003) and mice deleted for p53
(Donehower et al., 1992) (E/p53/, p53/) were maintained in a pure FVB/N
background. Mice carrying the GFAP-Ha-V12-Ras transgene were maintained
in a CD1 background. Genotypes were confirmed using PCR (Supplemental
Experimental Procedures). All experimental procedures involving animals in
this study were reviewed and approved by the Institutional Animal Care and
Use Committee at UCSF.
Cell Culture
Mouse cells were isolated from brain regions using a stereo-dissection micro-
scope (Leica). Tissues were dissociated using papain. Murine cells were
cultured in neurobasal (NB) media (-A, Invitrogen) supplemented with 1 3
B27 supplement, 20 ng/ml FGF-2 (Peprotech), 20 ng/ml EGF (Sigma-Aldrich),
2 mM L-glutamine, and incubated at 37C in 5% CO2. Human cells were used
after review and approval from the committee on human research at UCSF and
University of Rochester. Informed consent was obtained from all subjects. For
all assays, human glioma cells were cultured in NBEmedia that is similar to NB
(containing 0.53 B27 plus 0.53 N2 supplement (GIBCO) rather than 13 B27
supplement alone). Cell culture based assays are described in Supplemental
Experimental Procedures..
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To detect proliferating cells in mice, BrdU (Sigma-Aldrich) was injected IP at
2 hr before sacrifice (50 mg/kg). Paraffin-embedded (5 mm) and fixed (4%
para-formaldehyde) free-floating (30 mm) sections were used for light micros-
copy and fluorescent stainings. See Supplemental Experimental Procedures.
Real-Time Polymerase Chain Reaction
For details on quantitative RT-PCR, see Supplemental Experimental
Procedures.
Grafting Experiments
FACS-sorted human glioma cells (1000–10,000 cells/mouse) or FACS-sepa-
rated mouse tumor cells (50–1000 cells) isolated from E/p53/ mice were
intracranially grafted into anaesthetized (Ketamine andmethamidine) recipient
NOD-SCID and FVB/N mice.
Statistical Analysis
Statistical analyzes for all experiments including more than two groups were
performed using a two-way ANOVA followed by post hoc comparisons using
Dunnett’s post hoc test. For experiments with two groups, we used Student’s t
test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at doi:10.1016/
j.ccr.2010.10.033.
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